Skandinaviska Enskilda Banken (SEB)’s NeoGenomics NEO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
Sell
-41,500
Closed -$671K 895
2023
Q4
$671K Buy
41,500
+21,000
+102% +$344K ﹤0.01% 743
2023
Q3
$253K Buy
+20,500
New +$305K ﹤0.01% 818
2022
Q3
Sell
-39,626
Closed -$323K 988
2022
Q2
$323K Buy
39,626
+16,279
+70% +$155K ﹤0.01% 854
2022
Q1
$284K Sell
23,347
-11,591
-33% -$244K ﹤0.01% 871
2021
Q4
$1.19M Hold
34,938
0.01% 744
2021
Q3
$1.69M Buy
34,938
+7,027
+25% +$325K 0.01% 694
2021
Q2
$1.26M Buy
27,911
+805
+3% +$35.7K 0.01% 771
2021
Q1
$1.31M Sell
27,106
-207
-0.8% -$10.8K 0.01% 773
2020
Q4
$1.47M Buy
27,313
+591
+2% +$26.7K 0.01% 734
2020
Q3
$986K Buy
26,722
+26,119
+4,332% +$971K 0.01% 740
2020
Q2
$19K Buy
+603
New +$16.7K ﹤0.01% 1019

Other funds holding NEO

Skandinaviska Enskilda Banken (SEB)'s NEO Position: Q1 2024 in Review

Skandinaviska Enskilda Banken (SEB) sold out of NeoGenomics (NEO) in Q1 2024, closing a stake of 41,500 shares — an estimated $671K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in NEO in Q2 2020 and held it in 11 quarters. The position peaked at $1.69M in Q3 2021. 263 funds tracked by Wall St. Rank hold NEO as of Q1 2024.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining NeoGenomics position as of Q1 2024 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 41,500 NeoGenomics shares in Q1 2024, an estimated $671K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in NeoGenomics in Q2 2020 and held it in 11 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s NeoGenomics position peaked at $1.69M in Q3 2021.
  • 263 funds tracked by Wall St. Rank held NeoGenomics as of Q1 2024.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q1 2024, filed 13 May 2024.